6/28/23, 10:01 PM EUCLID Pathway Feedback Search Clinical Topics Home Studies EUCLID EUCLID Disease Peripheral artery disease of low Trial question What is the effect of ticagrelor in patients with symptomatic PAD? Study design Multi-center Double blinded RCT Population Characteristics of study participants 28.0% female N = 13885 72.0% male 13885 patients (3888 female, 9997 male) Inclusion criteria: patients with symptomatic PAD who had an ABI of 0.80 or had undergone previous revascularization of the lower limbs Key exclusion criteria: current or planned use of dual antiplatelet therapy or aspirin, an increased risk of bleeding, treatment with long-term anticoagulation, or a poor clopidogrel metabolizer status for the cytochrome P-450 2C19 allele Interventions N=6930 ticagrelor (90 mg BID) N=6955 clopidogrel (75 mg once daily) Primary outcome Cardiovascular death, myocardial infarction, or ischemic stroke 10.8 % 10.8 10.6 8 1 % https://web.pathway.md/studies/recDEz1rgTJMlOk06 1/2 6/28/23, 10:01 PM EUCLID Pathway 8.1 % 5.4 % 2.7 % No significant difference 0.0 % Ticagrelor Clopidogrel No significant difference in cardiovascular death, myocardial infarction, or ischemic stroke (10.8% vs. 10.6%; HR 1.02, 95% CI 0.92 to 1.13) Secondary outcomes No significant difference in acute limb ischemia (1.7% vs. 1.7%; HR 1.03, 95% CI 0.79 to 1.33) Safety outcomes No significant differences in major bleeding (1.6% in each group, p=0.49; HR 1.10, 95% CI 0.84- 1.43). Conclusion In patients with symptomatic PAD who had an ABI of 0.80 or had undergone previous revascularization of the lower limbs, ticagrelor was not superior to clopidogrel with respect to cardiovascular death, myocardial infarction, or ischemic stroke. Reference Hiatt WR, Fowkes FG, Heizer G et al. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med. 2017 Jan 5;376(1):32-40. Open reference URL https://web.pathway.md/studies/recDEz1rgTJMlOk06 2/2